Interferon beta (IFNβ), used in the management of multiple sclerosis for more than two decades, is among the currently recommended first-line disease-modifying therapies for patients with relapsing-remitting multiple sclerosis (RRMS) [1]. Here, IFNB1 is linked to relapsing-remitting multiple sclerosis.